Answers are grounded in this paper and cite their sources.
Background: Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy in which angiogenesis holds a pivotal role in tumor progression. The JAK/STAT signaling pathway is a crucial mechanism regulating angiogenesis. However, its upstream regulatory mechanisms in ESCC remain unclear. Methods: Differentially expressed OTX1 was identified using the TCGA data to analyze its prognostic value. The RM-2Target database was then employed to analyze the upstream regulator IGF2BP1 and its binding sites. The expression levels of OTX1 and related proteins were detected by RT-qPCR and Western blot. The effects of OTX1 on cell proliferation, migration, invasion, and angiogenesis in ESCC were evaluated by implementing CCK-8, transwell, wound healing, and tube formation assays. The regulatory role of OTX1 on the JAK/STAT pathway was investigated by employing the pathway activator, rIL-6. Finally, the interaction between OTX1 and IGF2BP1 was validated through RIP assay. Results: The expression level of OTX1 was significantly higher in ESCC tissues than in normal tissues (padj< 0.001). High OTX1 expression was significantly correlated with shortened overall survival in patients (HR = 2.22, Logrank P = 0.02). Knockdown of OTX1 in OE21 and KYSE410 cells reduced cell viability by more than 50%, and diminished cell migration and invasion capacities by nearly half, respectively. Consistently, OTX1 knockdown markedly decreased VEGFA protein levels and suppressed angiogenic capacity by 50% (P < 0.05). Mechanistic investigations revealed that OTX1 knockdown downregulated the levels of phosphorylated JAK2 (P-JAK2) and phosphorylated STAT3 (P-STAT3), whereas supplementation with recombinant interleukin-6 (rIL-6) reversed this phenotype. IG-F2BP1 expression was positively correlated with OTX1 expression (Pearson's r = 0.19, P < 0.05). Overexpression of IGF2BP1 nearly doubled the abundance of OTX1 mRNA, and this effect was abrogated by the m6A modification inhibitor STM2457. Conclusion: The study elucidates the molecular mechanism by which the IGF2BP1-OTX1 axis promotes angiogenesis and malignant progression in ESCC via activation of the JAK/STAT signaling pathway and identifies a novel potential therapeutic target for ESCC.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: